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Objectives: The prospective multinational Survey of Osteoarthritis Real World 
Therapies (SORT) was designed to investigate treatment patterns, adequacy of 
pain relief and quality of life in knee osteoarthritis (OA). This analysis describes 
the demographic and clinical characteristics most associated with inadequate 
pain relief (IPR) in knee OA in Portugal. MethOds: Male or female subjects aged 
≥ 50 years with primary knee OA and who were receiving oral or topical analgesics 
were enrolled between January and December 2011 at seven primary care cent-
ers. Pain was assessed using the Brief Pain Inventory (BPI). IPR was defined as a 
score > 4/10 on the BPI item “What is your pain on average?” reflecting moderate 
to severe disease. Multivariable logistic regression model was employed to iden-
tify the subject characteristics most associated with IPR. Results: Overall, 197 
consecutive patients were analyzed. The mean age was 67.0 ± 8.6 years and 78.2% 
were female. The mean duration of knee OA was 6.2 ± 6.3 years. The most com-
mon comorbidities were hypertension (64.0%), hyperlipidemia (58.4%), disability 
(41.6%) and depression (37.6%). Nonsteroidal antiinflammatory drugs were the 
most frequently used analgesics. IPR was reported by 51.3% of patients (95%CI 
44.1%, 58.4%). Disability, depression and diabetes were more frequent among 
patients with IPR than in patients with Non-IPR (p< 0.05). No statistically signifi-
cant differences were observed in the type and mean number of different classes 
of medication used by IPR and Non-IPR patients. Female gender (adjusted odds 
ratio - OR 2.15 [95%CI 1.1, 4.5]), diabetes (adjusted OR 3.1 [95%CI 1.3, 7.7]) and 
depression (adjusted OR 2.24 [95%CI 1.2, 4.3]) were associated with higher risk of 
IPR. cOnclusiOns: Our findings indicate that improvements are needed in the 
management of pain in knee OA in order to achieve better outcomes and highlight 
the requisite for further interventions targeting frequent comorbid conditions in 
knee OA in Portugal.
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Objectives: Rotator cuff tear of the shoulder is a common musculoskeletal disor-
der, may have a substantial impact on patients’ quality of life (QOL) and implies a 
significant cost burden. Arthroscopic rotator cuff repair (aRCR) is one established 
standard therapy, however, health services research has generated little infor-
mation about the impact of aRCR on QOL and on costs in real world settings. We 
aimed to assess the impact of aRCR in routine care in Switzerland. MethOds: In a 
prospective before-after study, consecutive patients with aRCR in a single tertiary 
orthopaedic centre were assessed for QOL using EQ-5D-5L to gain health states/
utilities (range: 0.00-1.00; multiple measurements from pre-operative enrolment 
until 2 years after surgery). Direct medical costs in Swiss Francs (CHF) were assessed 
from a third party payer perspective using health insurance claims data for 3 time 
intervals (1 year before surgery; year 1 and 2 after surgery). Results: 152 patients 
(mean age 57 years [range: 31-73]; male: 61%) were operated, of which 67 were evalu-
ated for QOL up to 12 months. QOL showed a stepwise improvement: 0.75 (mean 
utility at enrollment), 0.71 (pre-op), 0.61 (2 weeks), 0.85 (3 months), 0.91 (6 months), 
0.93 (12 months). Direct medical costs (mean, SD) of the first patients with cost 
data were CHF 7,540 (6,684) in the year before surgery (n= 47: mean inpatient: 882; 
outpatient: 6,658) and CHF 9,759 (3,675) in the first year after surgery (n= 40: mean 
inpatient: 4,964 [including operation]; outpatient: 4,795). cOnclusiOns: Patients 
with aRCR in routine care show a significant and clinically relevant improvement 
of QOL until 12 months after surgery. This is important information for decision 
makers in Switzerland. Completion of follow up of our patient cohort will allow a 
better understanding of the relationship between gain in QOL and involved direct 
medical costs.
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Objectives: The recently developed Forgotten Joint Score - 12 (FJS-12) is increas-
ingly being used in patients with hip or knee pathologies to assess joint aware-
ness following surgical or conservative treatment. Joint awareness is a construct 
considered to be especially relevant in patients with good to excellent outcome. In 
our study we aimed at investigating reliability, validity and sensitivity to change 
over time of the English version of the FJS-12 in patients with total knee arthro-
plasty (TKA) or total hip arthroplasty (THA). MethOds: Patients undergoing THA 
or TKA at the Royal Infirmary of Edinburgh were consecutively included in the 
study and assessed with the FJS-12 at pre-surgery, 6 months and 12 months. To 
determine convergent validity we administered the Oxford Hip Score (OHS) and 
the Oxford Knee Score (OKS). We calculated Cronbach’s Alpha as a measure of 
internal consistency of the FJS-12. Sensitivity to change is given as effect size 
(Cohen’s d). Results: At present we have recruited 219 TKA patients and 193 
THA patients (recruitment ongoing). Mean age of the TKA patients was 68.3 (SD 
9.3) and 54.1% were female. Mean age in the THA group was 67.6 years (SD 10.5) 
and 116 (60.1%) were female. Cronbach’s alpha was very high in both groups (0.95 
in TKA patients and 0.96 in THA patients). Correlations with the OHS (r= 0.76) and 
the OKS (r= 0.72) indicated good convergent validity of the FJS-12. Effect sizes 
for change between 6 months and 12 months in FJS-12 scores were 0.40 in TKA 
patients and d= 0.17 in THA patients. cOnclusiOns: The English version of 
the FJS-12 showed high internal consistency in THA and TKA patients and good 
convergent validity with the OHS and OKS. Our findings suggest that the FJS-
12 is a reliable and valid instrument for the assessment of outcome after THA 
and TKA.
patient organizations wasn’t perceived significant. Areas that have improved com-
pared to the period of patients starting their treatment: communication with health-
care personnel (80%), more effective therapies available (65%). cOnclusiOns: This 
study showed significant impact of the rheumatic diseases on work capabilities and 
socio-economic status. The results of the research were presented and discussed with 
the patient community and rheumatologists and on their respective conferences.
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Objectives: Chronic autoimmune diseases such as rheumatoid arthritis (RA) 
require continuous disease modifying medication to influence disease progres-
sion. Real-life efficacy of treatments rests on adherence. Since patients’ beliefs 
impact on adherence, adherence could be supported by treatments better respect-
ing these beliefs. Thus, using an RA sample, the present study establishes in how 
far patients’ beliefs are reflected by their preferences for treatment characteristics 
of disease-modifying anti-rheumatic drugs (DMARDs). MethOds: Preferences 
were assessed in a choice experiment (Best-Worst Scaling). 1588 RA patients were 
asked to choose most and least preferred DMARDs among treatment options with 
varying levels of the following key attributes: mode of administration, frequency 
of administration, time till onset of drug effect, necessity of combination therapy, 
and side effects. Patients were classified into groups of “accepting”, “ambivalent”, 
“sceptical”, and “indifferent” patients (Clifford et al., 2008) according to a modified 
“beliefs about medicines”-questionnaire. Utilities of attribute levels were assessed 
by paired model regression analysis (Flynn et al., 2007) and compared between 
groups. Regression analysis was conducted to control for confounding patient-
related variables. Results: Majority of patients were female (74%), 50 to 64 years 
of age (45%), with < 10 years of disease duration (54%), and were receiving DMARDs 
(95%). Mode of administration appeared the most important attribute, with “oral 
application“ being most desired. Second most relevant attribute was “necessity 
of combination therapy with MTX”, followed by frequency of administration, side 
effects and time to onset of effect. Preferences concerning “mode of administration” 
and “tolerance of side effects” were significantly different between subjects clas-
sified by their beliefs about medicines”, according to regression analysis adjusting 
for confounding patient-related variables. cOnclusiOns: Results indicate beliefs 
about medicines to be meaningfully associated with patient preferences regard-
ing DMARD characteristics. This offers important leads to improving adherence by 
designing more consumer-friendly pharmaceutical products for chronic diseases.
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Objectives: To synthesize the available information on patients’ preferences for 
rheumatoid arthritis (RA) treatment and their participation in the treatment deci-
sion-making process. MethOds: Electronic databases [PubMed, ISI-WOK, Cochrane 
Library, MEDES, IBECS, CSIC] and grey literature, were searched. Studies written in 
English or Spanish, published in Europe and North America between January 2005 
and February 2015 were selected. Editorials, letters, opinion papers and studies 
performed on specific populations were excluded. Results: The search resulted in 
1,156 citations; 15 studies accomplished the selection criteria. Nine studies explored 
patients’ preferences for RA treatments characteristics (administration methods= 7; 
frequency= 2). Auto-injected devices that facilitated self-administration at home 
and improved comfort, and less frequent doses were preferred. Convenience (home 
administration and non-interference with everyday life) was the main reason for 
choosing subcutaneous routes, while safety, rapidity of action, reassurance and con-
fidence were the reasons for choosing intravenous routes. Two publications exam-
ined the influence of patients’ characteristics on treatment status-quo. Patients 
who were moderately affected by RA were more open to consider new treatment 
alternatives. One study explored patients’ priorities regarding treatment outcomes. 
Less pain, joint damage or fatigue, daily life activities and more mobility were the 
prioritized outcomes. Three studies elicited preferences regarding patients’ par-
ticipation in treatment decision-making, showing that they were negatively asso-
ciated with age but positively associated with RA knowledge. Although patients 
preferred shared treatment decision-making, they reported that most of the phy-
sician-patients communication was centered on symptoms and impact of RA. Most 
patients valued treatment recommendations given by their physicians considering 
their expert knowledge and clinical experience. Unawareness of having a choice 
was the main barrier for patients’ participation in decision-making. cOnclusiOns: 
Patients’ preferences are influenced by patients’ characteristics, clinical status and 
impact of RA in their daily life. Including patients’ preference and involving patients 
in treatment decision-making may contribute to better clinical outcomes.
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